Dynavax Technologies Corporation (0IDA.L)
USD 14.02
(-3.7%)
USD 14.02
(-3.7%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 256.91 Million USD | -0.42% |
| 2022 | 258.01 Million USD | 0.24% |
| 2021 | 257.38 Million USD | 18.15% |
| 2020 | 217.84 Million USD | 0.65% |
| 2019 | 216.44 Million USD | 114.58% |
| 2018 | 100.87 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 9.55 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 12.81 Million USD | 8.73% |
| 2010 | 11.78 Million USD | 26.12% |
| 2009 | 9.34 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 256.1 Million USD | -0.32% |
| 2024 Q2 | 255.28 Million USD | -0.32% |
| 2023 Q3 | 253.09 Million USD | -1.84% |
| 2023 Q2 | 257.82 Million USD | 1.51% |
| 2023 Q1 | 253.98 Million USD | -1.56% |
| 2023 Q4 | 256.91 Million USD | 1.51% |
| 2023 FY | 256.91 Million USD | -0.42% |
| 2022 Q4 | 258.01 Million USD | 0.08% |
| 2022 FY | 258.01 Million USD | 0.24% |
| 2022 Q2 | 257.74 Million USD | -0.09% |
| 2022 Q3 | 257.81 Million USD | 0.03% |
| 2022 Q1 | 257.98 Million USD | 0.23% |
| 2021 Q4 | 257.38 Million USD | -0.25% |
| 2021 FY | 257.38 Million USD | 18.15% |
| 2021 Q2 | 256.34 Million USD | 18.11% |
| 2021 Q1 | 217.04 Million USD | -0.37% |
| 2021 Q3 | 258.04 Million USD | 0.66% |
| 2020 FY | 217.84 Million USD | 0.65% |
| 2020 Q2 | 218.93 Million USD | -0.26% |
| 2020 Q3 | 218.4 Million USD | -0.24% |
| 2020 Q4 | 217.84 Million USD | -0.25% |
| 2020 Q1 | 219.5 Million USD | 1.41% |
| 2019 Q3 | 214.57 Million USD | 1.56% |
| 2019 Q2 | 211.27 Million USD | 0.25% |
| 2019 Q1 | 210.74 Million USD | 108.93% |
| 2019 FY | 216.44 Million USD | 114.58% |
| 2019 Q4 | 216.44 Million USD | 0.87% |
| 2018 FY | 100.87 Million USD | 0.0% |
| 2018 Q1 | 99.23 Million USD | 0.0% |
| 2018 Q2 | 99.77 Million USD | 0.54% |
| 2018 Q4 | 100.87 Million USD | 0.55% |
| 2018 Q3 | 100.31 Million USD | 0.55% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q1 | 9.5 Million USD | -0.54% |
| 2015 Q2 | 9.45 Million USD | -0.5% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 9.55 Million USD | 0.0% |
| 2014 Q4 | 9.55 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 FY | - USD | -100.0% |
| 2012 Q2 | 13.9 Million USD | 4.1% |
| 2012 Q3 | 14.45 Million USD | 3.93% |
| 2012 Q4 | - USD | -100.0% |
| 2012 Q1 | 13.35 Million USD | 4.27% |
| 2011 FY | 12.81 Million USD | 8.73% |
| 2011 Q4 | 12.81 Million USD | 3.79% |
| 2011 Q2 | 12.73 Million USD | 11.63% |
| 2011 Q1 | 11.4 Million USD | -3.18% |
| 2011 Q3 | 12.34 Million USD | -3.08% |
| 2010 Q1 | 12.85 Million USD | 37.55% |
| 2010 Q4 | 11.78 Million USD | 2.59% |
| 2010 Q3 | 11.48 Million USD | -13.66% |
| 2010 Q2 | 13.3 Million USD | 3.51% |
| 2010 FY | 11.78 Million USD | 26.12% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | 9.34 Million USD | 0.0% |
| 2009 Q4 | 9.34 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 77.342% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -8257.645% |
| Myriad Genetics, Inc. | 145 Million USD | -77.182% |
| Evolus, Inc. | 126.54 Million USD | -103.02% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 82.325% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 90.606% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -350.821% |
| uniQure N.V. | 138.4 Million USD | -85.619% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -343.935% |
| bluebird bio, Inc. | 330.32 Million USD | 22.224% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -5736.302% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 89.286% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -170041.722% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 42.274% |
| Editas Medicine, Inc. | 36.53 Million USD | -603.18% |
| FibroGen, Inc. | 170.45 Million USD | -50.722% |
| Geron Corporation | 85.89 Million USD | -199.088% |
| Blueprint Medicines Corporation | 774.12 Million USD | 66.812% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 98.195% |
| Illumina, Inc. | 2.26 Billion USD | 88.642% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -25591.4% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -607.304% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 40.029% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -495.163% |
| Adicet Bio, Inc. | 17.7 Million USD | -1351.246% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 81.607% |
| Insmed Incorporated | 1.2 Billion USD | 78.662% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -122.733% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 88.148% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -851.886% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -518.667% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 97.311% |
| Waters Corporation | 2.35 Billion USD | 89.093% |
| Zoetis Inc. | 6.8 Billion USD | 96.224% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.264% |
| Biogen Inc. | 7.33 Billion USD | 96.499% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -574.244% |
| Nektar Therapeutics | 230.4 Million USD | -11.507% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -20290.0% |
| Perrigo Company plc | 4.07 Billion USD | 93.693% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -37.85% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -47.862% |
| Verastem, Inc. | 41.55 Million USD | -518.221% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 68.219% |
| Imunon, Inc. | 1.13 Million USD | -22450.301% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -1130.182% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 52.507% |
| Homology Medicines, Inc. | 44.05 Million USD | -483.18% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 90.495% |
| OPKO Health, Inc. | 326.56 Million USD | 21.328% |
| Exelixis, Inc. | 189.94 Million USD | -35.258% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 82.864% |
| TG Therapeutics, Inc. | 110.79 Million USD | -131.882% |
| Incyte Corporation | 38.28 Million USD | -571.021% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 70.722% |